IKS03 Shows Early Activity in Relapsed B Cell Lymphoma

Company Iksuda Therapeutics Event Type Phase 1 dose-escalation data Modality Antibody-drug conjugate (prodrug PBD payload) Asset IKS03 Target CD19 Disease Area Relapsed or refractory B-cell non-Hodgkin lymphoma Summary Iksuda disclosed first Phase 1 dose-escalation data for CD19-directed prodrug ADC IKS03 on November 5. Nine of…